NCT07515027 Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung Cancer Surgery
| NCT ID | NCT07515027 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai Chest Hospital |
| Condition | PONV |
| Study Type | INTERVENTIONAL |
| Enrollment | 204 participants |
| Start Date | 2026-04-07 |
| Primary Completion | 2026-11-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 204 participants in total. It began in 2026-04-07 with a primary completion date of 2026-11-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective, randomized controlled study aims to evaluate the efficacy and safety of electroacupuncture combined with 5-HT3 receptor inhibitor for preventing postoperative nausea and vomiting (PONV) in high-risk patients undergoing thoracoscopic lung cancer surgery. The primary outcome is the incidence of PONV within 24 hours after surgery.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years; * American Society of Anesthesiologists (ASA) physical status I-III; * Body mass index (BMI) 18-30 kg/m²; * Scheduled for elective video-assisted thoracoscopic surgery (VATS) lobectomy, segmentectomy, or wedge resection; * Expected to receive postoperative opioid analgesia, with an Apfel risk score ≥ 3; * Normal pulmonary function, without severe cardiovascular, hepatic, or renal abnormalities; * No infection around the acupuncture sites; * Voluntary written informed consent provided by the subject. Exclusion Criteria: * Severe systemic diseases, such as cardiovascular, hepatic, or renal abnormalities, or poor pulmonary function; * Subjects with cognitive dysfunction or psychological disorders; * History of previous esophageal or gastric surgery; * Hypersensitivity to acupuncture or any study medications; * Severe infection or history of surgery around the acupuncture sites; * Pregnant or lactating women; * Long-term opioid use; * Conversion to open surgery; * Acupuncture treatment received within 1 month prior to enrollment.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07515027 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying PONV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07515027 currently recruiting?
Yes, NCT07515027 is actively recruiting participants. Contact the research team at caixiaoyue2007@163.com for enrollment information.
Where is the NCT07515027 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07515027 clinical trial?
NCT07515027 is sponsored by Shanghai Chest Hospital. The trial plans to enroll 204 participants.